Cargando…
Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas
Recurrences of Hodgkin's Lymphoma (HL) 5 years after the initial therapy are rare. The aim of this study is to report a single centre experience of the clinical characteristics, outcome, and toxicity of pts who experienced very late relapses, defined as relapses that occurred 5 or more years af...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023035/ https://www.ncbi.nlm.nih.gov/pubmed/21253449 http://dx.doi.org/10.1155/2011/707542 |
_version_ | 1782196629098463232 |
---|---|
author | Gaudio, Francesco Giordano, Annamaria Pavone, Vincenzo Perrone, Tommasina Curci, Paola Pastore, Domenico Delia, Mario de' Risi, Clara Spina, Alessandro Liso, Vincenzo Specchia, Giorgina |
author_facet | Gaudio, Francesco Giordano, Annamaria Pavone, Vincenzo Perrone, Tommasina Curci, Paola Pastore, Domenico Delia, Mario de' Risi, Clara Spina, Alessandro Liso, Vincenzo Specchia, Giorgina |
author_sort | Gaudio, Francesco |
collection | PubMed |
description | Recurrences of Hodgkin's Lymphoma (HL) 5 years after the initial therapy are rare. The aim of this study is to report a single centre experience of the clinical characteristics, outcome, and toxicity of pts who experienced very late relapses, defined as relapses that occurred 5 or more years after the achievement of first complete remission. Of 532 consecutive pts with classical HL treated at our Institute from 1985 to 1999, 452 pts (85%) achieved a complete remission. Relapse occurred in 151 pts: 135 (29.8%) within 5 years and 16 over 5 years (3.5%, very late relapses). Very late relapses occurred after a median disease-free interval of 7 years (range: 5–18). Salvage treatment induced complete remission in 14 pts (87.5%). At a median of 4 years after therapy for very late relapse, 10 pts (63%) are still alive and free of disease and 6 (37%) died (1 from progressive HL, 1 from cardiac disease, 1 from thromboembolic disease, 1 from HCV reactivation, and 2 from bacterial infection). The probability of failure-free survival at 5 years was 75%. The majority of deaths are due to treatment-related complications. Therapy regimens for very late relapse HL are warranted to minimize complications. |
format | Text |
id | pubmed-3023035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-30230352011-01-20 Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas Gaudio, Francesco Giordano, Annamaria Pavone, Vincenzo Perrone, Tommasina Curci, Paola Pastore, Domenico Delia, Mario de' Risi, Clara Spina, Alessandro Liso, Vincenzo Specchia, Giorgina Adv Hematol Clinical Study Recurrences of Hodgkin's Lymphoma (HL) 5 years after the initial therapy are rare. The aim of this study is to report a single centre experience of the clinical characteristics, outcome, and toxicity of pts who experienced very late relapses, defined as relapses that occurred 5 or more years after the achievement of first complete remission. Of 532 consecutive pts with classical HL treated at our Institute from 1985 to 1999, 452 pts (85%) achieved a complete remission. Relapse occurred in 151 pts: 135 (29.8%) within 5 years and 16 over 5 years (3.5%, very late relapses). Very late relapses occurred after a median disease-free interval of 7 years (range: 5–18). Salvage treatment induced complete remission in 14 pts (87.5%). At a median of 4 years after therapy for very late relapse, 10 pts (63%) are still alive and free of disease and 6 (37%) died (1 from progressive HL, 1 from cardiac disease, 1 from thromboembolic disease, 1 from HCV reactivation, and 2 from bacterial infection). The probability of failure-free survival at 5 years was 75%. The majority of deaths are due to treatment-related complications. Therapy regimens for very late relapse HL are warranted to minimize complications. Hindawi Publishing Corporation 2011 2010-12-29 /pmc/articles/PMC3023035/ /pubmed/21253449 http://dx.doi.org/10.1155/2011/707542 Text en Copyright © 2011 Francesco Gaudio et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Gaudio, Francesco Giordano, Annamaria Pavone, Vincenzo Perrone, Tommasina Curci, Paola Pastore, Domenico Delia, Mario de' Risi, Clara Spina, Alessandro Liso, Vincenzo Specchia, Giorgina Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas |
title | Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas |
title_full | Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas |
title_fullStr | Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas |
title_full_unstemmed | Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas |
title_short | Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas |
title_sort | outcome of very late relapse in patients with hodgkin's lymphomas |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023035/ https://www.ncbi.nlm.nih.gov/pubmed/21253449 http://dx.doi.org/10.1155/2011/707542 |
work_keys_str_mv | AT gaudiofrancesco outcomeofverylaterelapseinpatientswithhodgkinslymphomas AT giordanoannamaria outcomeofverylaterelapseinpatientswithhodgkinslymphomas AT pavonevincenzo outcomeofverylaterelapseinpatientswithhodgkinslymphomas AT perronetommasina outcomeofverylaterelapseinpatientswithhodgkinslymphomas AT curcipaola outcomeofverylaterelapseinpatientswithhodgkinslymphomas AT pastoredomenico outcomeofverylaterelapseinpatientswithhodgkinslymphomas AT deliamario outcomeofverylaterelapseinpatientswithhodgkinslymphomas AT derisiclara outcomeofverylaterelapseinpatientswithhodgkinslymphomas AT spinaalessandro outcomeofverylaterelapseinpatientswithhodgkinslymphomas AT lisovincenzo outcomeofverylaterelapseinpatientswithhodgkinslymphomas AT specchiagiorgina outcomeofverylaterelapseinpatientswithhodgkinslymphomas |